{"id":"https://openalex.org/G7745859898","display_name":"CARGO: advancing chimeric antigen receptor T cell therapy using nanobody-displaying lentiviral vectors.","description":"Research into adoptive T cell therapy for cancer is trending. Herein, the focus lies on chimeric antigen receptor engineered T (CAR-T) cells as evidenced by over 100 companies investing in CAR-T cell technology. This is explained by the success achieved by CAR-T cells in hematological malignancies. However, similar results have not been obtained in the context of solid tumors. Among the top priorities to develop an affordable and effective CAR-T cell therapy for solid tumors is simplifying the CAR-T cell manufacturing process and improving the design of the CAR as well as the armor of the T cell. In the CARGO-project, we will work on these aspects, building on innovative technologies developed at the VUB, in particular nanobodies (Nbs), to develop T cell-targeted Nb-displaying lentiviral vectors (LVs) harboring Nb-engineered CARs (nanoCARs) and when required factors that enhance T cell homing, tumor infiltration and functionality. We will study LVs displaying cross-reactive CD3-, CD4- or CD8-targeted Nbs that harbor T cell enhancing factors in addition to nanoCARs directed against HER2. We will study these LVs using breast cancer spheroids generated with HER2+ cells of human or mouse origin as well as in immunocompetent mouse models. The latter will provide an in-depth preclinical analysis of the potential of the in vivo nanoCAR-T cell approach, and as such will open the path to clinical translation.","funder_award_id":"1S68521N","funder":{"id":"https://openalex.org/F4320321730","display_name":"Fonds Wetenschappelijk Onderzoek","doi":"https://doi.org/10.13039/501100003130"},"funded_outputs":["https://openalex.org/W3165252338"],"funded_outputs_count":1,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":null,"currency":null,"amount_usd":null,"amount_usd_basis":null,"recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"grant","funder_scheme":"FWO Strategic Basic Research Grant","start_date":"2020-11-01","end_date":"2022-10-31","start_year":2020,"end_year":2022,"landing_page_url":"https://researchportal.be/en/project/76fdeabd-32e0-437d-8c0a-be3378c625b4","doi":null,"provenance":"fwo_fris","lead_investigator":{"given_name":"Fien","family_name":"Meeus","orcid":null,"role_start":null,"affiliation":{"name":"FWO","country":"BE","ids":null},"author":{"id":"https://openalex.org/A5088608394","display_name":"Fien Meeus","orcid":"https://orcid.org/0000-0002-5866-2002"},"institutions":[{"id":"https://openalex.org/I2802067006","display_name":"Research Foundation - Flanders","ror":"https://ror.org/03qtxy027","country_code":"BE","type":"government","lineage":["https://openalex.org/I2802067006"]}]},"co_lead_investigator":{"given_name":"Nick","family_name":"Devoogdt","orcid":null,"role_start":null,"affiliation":{"name":"FWO","country":"BE","ids":null},"author":{"id":"https://openalex.org/A5067597833","display_name":"Nick Devoogdt","orcid":"https://orcid.org/0000-0001-9220-4833"},"institutions":[{"id":"https://openalex.org/I2802067006","display_name":"Research Foundation - Flanders","ror":"https://ror.org/03qtxy027","country_code":"BE","type":"government","lineage":["https://openalex.org/I2802067006"]}]},"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G7745859898","primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9912,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9912,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.0052,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0011,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.935},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.862},{"id":"https://openalex.org/keywords/nanobodies","display_name":"nanobodies","score":0.844},{"id":"https://openalex.org/keywords/lentiviral-vectors","display_name":"lentiviral vectors","score":0.959},{"id":"https://openalex.org/keywords/nanocars","display_name":"nanocars","score":0.814},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.714},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.778},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.899},{"id":"https://openalex.org/keywords/t-cell-homing","display_name":"T cell homing","score":0.902},{"id":"https://openalex.org/keywords/tumor-infiltration","display_name":"tumor infiltration","score":0.878},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.767},{"id":"https://openalex.org/keywords/cd3","display_name":"CD3","score":0.465},{"id":"https://openalex.org/keywords/cd4","display_name":"CD4","score":0.996},{"id":"https://openalex.org/keywords/cd8","display_name":"CD8","score":0.872},{"id":"https://openalex.org/keywords/spheroids","display_name":"spheroids","score":0.653},{"id":"https://openalex.org/keywords/immunocompetent-mouse-model","display_name":"immunocompetent mouse model","score":0.88}],"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763}],"institution_awarded":[{"id":"https://openalex.org/I2802067006","display_name":"Research Foundation - Flanders","ror":"https://ror.org/03qtxy027","country_code":"BE","type":"government","lineage":["https://openalex.org/I2802067006"]}],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-07-13T04:54:19.000Z"}
